Massachusetts is home to a thriving pharmaceutical industry, with leading companies pushing the boundaries of drug discovery and biopharmaceutical advancements. From cannabinoid-based therapies by Targeted Pharmaceuticals in Worcester to oncology-focused innovations by TESARO in Waltham, these firms are at the forefront of cutting-edge research in personalized medicine and biotech. Investment opportunities abound in sectors such as oncology, neurology, and antimicrobial resistance, driven by Massachusetts' robust ecosystem of publicly traded companies and dynamic startups.
Ra Pharmaceuticals specializes in pharmaceutical manufacturing, focusing on innovative therapies for rare diseases. Its unique approach includes the development of peptide-based treatments, enhancing the effectiveness and precision of drug delivery.
Engaged in biotechnology research, Synspira Therapeutics focuses on innovative therapeutic solutions, emphasizing advancements in treatment methodologies.
Dyax specializes in biotechnology research, focusing on innovative approaches to develop therapies for rare diseases. Its expertise in this niche area enhances its contributions to the biotechnology industry.
Aurora Biopharma, Inc. specializes in research services within the biopharmaceutical industry, focusing on innovative approaches to drug development and therapeutic solutions.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative antiviral therapies for COVID-19 and severe viral diseases, addressing critical unmet medical needs in the biotechnology research industry.
Focused on the discovery and development of treatments for neurodegenerative diseases, this pharmaceutical manufacturer specializes in addressing conditions such as ALS, employing a collaborative approach to enhance the lives of those affected.
Bach Pharma operates in the biotechnology industry, focusing on innovative solutions for pharmaceutical development and production. Their unique approach emphasizes advanced biotechnological methods to enhance drug efficacy and safety.
Kiniksa Pharmaceuticals specializes in biotechnology research, concentrating on the discovery, development, and commercialization of therapeutic medicines for patients with debilitating diseases and significant unmet medical needs. The organization emphasizes a robust pipeline and a skilled team to deliver transformative therapies, showcasing a commitment to innovation and rapid execution in the biopharmaceutical sector.
Targeted Pharmaceuticals specializes in cannabinoid-based drug discovery and personalized medicine within the pharmaceutical manufacturing industry, focusing on innovative approaches to developing tailored therapeutic solutions.
Censa Pharmaceuticals is focused on developing innovative medicines aimed at improving the lives of patients suffering from debilitating diseases within the biotechnology research industry.
Arsanis specializes in biotechnology research, focusing on innovative solutions in the pharmaceutical sector. The firm is positioned for growth following its merger with X4 Pharmaceuticals, enhancing its capabilities in developing advanced therapeutic options.
VDA Pharma, Inc. specializes in the manufacturing of biopharmaceuticals focused on HIV treatment, leveraging innovative approaches to develop effective therapies in the pharmaceutical industry.
Akashi Therapeutics is a clinical stage biotechnology firm focused on developing innovative therapies for Duchenne muscular dystrophy and other rare diseases, with a strong emphasis on muscle regeneration and anti-inflammatory properties through its lead asset HT-100 and the muscle-building SARM DT-200. The organization is distinguished by its foundation through collaboration between patient advocacy groups and seasoned biotechnology professionals.
Ardelyx, Inc. specializes in biotechnology research, focusing on the discovery and commercialization of innovative, first-in-class medicines to address significant unmet medical needs. The firm is notable for its development of tenapanor, with multiple approved products targeting conditions such as irritable bowel syndrome and hyperphosphatemia.
TAC Biopharmaceuticals specializes in biotechnology research, offering a comprehensive suite of services that support the development and commercialization of biopharmaceuticals, including generic drugs and biosimilars. With over 25 years of industry experience and a strong emphasis on regulatory expertise and strategic guidance, it empowers clients to navigate the complexities of modern medicine development.
Ascent Therapeutics specializes in biotechnology research, focusing on innovative therapeutic solutions aimed at advancing healthcare. Their unique approach leverages cutting-edge technology to develop novel treatments for various medical conditions.
Boston Life Sciences Inc specializes in biotechnology research, focusing on innovative solutions and advanced methodologies to drive breakthroughs in the life sciences sector.
Tarix Pharmaceuticals LTD specializes in biotechnology research, focusing on innovative therapeutic solutions to address unmet medical needs. Their unique approach emphasizes the development of novel treatments, positioning them as a key player in advancing healthcare.
A fully integrated biopharmaceutical solutions provider, specializing in both clinical and commercial services, that leverages expertise, data, and insights to enhance biopharmaceutical performance in an increasingly complex market. Its unique approach combines Contract Research Organization (CRO) and Contract Commercial Organization (CCO) capabilities to support a wide range of pharmaceutical and biotechnology needs.
Hypromatrix Inc specializes in biotechnology research, focusing on innovative solutions and advancements in the field. Their expertise positions them at the forefront of developing cutting-edge biotechnological applications.
eXIthera Pharmaceuticals specializes in pharmaceutical manufacturing, focusing on innovative therapeutic solutions. The firm is dedicated to advancing healthcare through the development of novel treatments.
Platform Therapeutics specializes in biotechnology research, focusing on developing innovative medicines for critically ill patients. Their commitment to addressing urgent medical needs sets them apart in the healthcare industry.
Nuvelution Pharmaceuticals specializes in biotechnology research, focusing on maximizing the potential of pharmaceutical portfolios through innovative strategies and approaches.
NeuroPhage Pharmaceuticals specializes in biotechnology research, focusing on innovative therapies to combat neurodegenerative diseases. Their unique approach leverages cutting-edge science to develop treatments that target the underlying mechanisms of these conditions.
A pre-competitive consortium in biotechnology research focused on qualifying, validating, and operationalizing EEG/ERP biomarkers for CNS clinical trials, fostering collaboration among industry, academic, and regulatory stakeholders to enhance the reliability of these biomarkers in clinical settings.
Novelion Therapeutics focuses on developing innovative biopharmaceuticals aimed at establishing new standards of care for rare diseases, with a diverse portfolio that includes treatments for metabolic disorders and ongoing research into therapies for inherited retinal diseases. Their commitment to advancing science and clinical development distinguishes them in the biotechnology research industry.
Manta Medicines operates in the biotechnology research industry, focusing on developing innovative medicines aimed at undrugged targets. The organization emphasizes a strategic selection of programs with the potential for multiple indications, aiming to create a diverse portfolio that mitigates risk while enhancing the likelihood of clinical success.
Oxeia Biopharmaceuticals is focused on developing innovative therapeutics for mild traumatic brain injury (concussion) and related neuro-metabolic dysfunction, with a clinical-stage drug, OXE103, currently undergoing Phase 2 trials. Their unique approach addresses a significant gap in treatment options for concussion patients, emphasizing the need for more than just rest.
Specializing in biotechnology research, this clinical biopharmaceutical entity is dedicated to improving the lives of individuals with rare immune disorders by developing innovative treatments, notably mavorixafor, which has gained FDA approval for its first indication. Their patient-centric approach and focus on advancing therapies for underserved populations highlight their commitment to addressing critical healthcare needs.
Alnylam Pharmaceuticals is a pioneering biopharmaceutical entity specializing in RNA interference (RNAi) therapeutics, which offers an innovative approach to silencing disease-causing genes. With a robust pipeline of approved therapies, it is at the forefront of developing treatments for both rare and prevalent diseases.
Updated on
Save time, improve accuracy, and get ahead of the competition with Cenco.ai.
Get startedTop 25 Residential Property Management Specialists in Texas
Explore Texas's top 25 residential property management specialists, offering unique investment strategies and sector-focused solutions.
Top 20 Dental Insurance Companies in California
Discover the top 20 dental insurance companies in California, featuring insights into unique offerings, market focus, and specialized health solutions.
Top 21 window installation companies in the US
Discover the top 21 window installation companies in the US, focusing on energy efficiency, innovative designs, and sustainable building practices.